On July 9, 2024, the FDA approved Zoryve (roflumilast) cream 0.15 percent as a treatment for atopic dermatitis. This steroid-free topical solution offers a new option for managing this common form of eczema.
Key highlights of Zoryve include its rapid effectiveness, with users experiencing relief from itch, the primary symptom of atopic dermatitis, in as little as 24 hours. Clinical trials showed minimal and mild side effects, making it a safe option for long-term use.
As a non-steroidal treatment, Zoryve cream can be applied for extended periods without the risks associated with steroid-based medications.
FDA Approves Zoryve for Atopic Dermatitis: A New Era in Eczema Treatment
In a significant advancement for dermatology, the U.S. Food and Drug Administration (FDA) has approved Zoryve (roflumilast) cream 0.15 percent for the treatment of atopic dermatitis. The approval, announced on July 9, 2024, offers new hope for adults and children aged six and older suffering from this chronic skin condition, which is the most common form of eczema. Zoryve is a once-daily, steroid-free topical treatment that provides rapid relief with fewer side effects compared to traditional treatments. Its safety profile allows for extended use, offering a valuable option for those who need long-term care.
Why Zoryve Matters: Filling a Treatment Gap
Atopic dermatitis is often managed with regular moisturizing and self-care, but for some, these methods are not enough to control the condition. “The mainstay of treatment for atopic dermatitis for decades has been topical steroids, which are not safe for long-term use, and topical calcineurin inhibitors, which are often not tolerable due to a burning sensation,” explains Ray Kleinfelder, DO, a dermatologist in Santa Barbara, California. The need for alternatives is critical, particularly for patients with sensitive skin or those who require ongoing treatment.
Zoryve meets this need by offering a steroid-free option that can be used continuously without the risks associated with long-term steroid use. According to Lawrence Eichenfeld, MD, a pediatric dermatologist and professor at the University of California in San Diego, Zoryve provides a much-needed alternative for patients whose symptoms are not effectively managed with standard treatments. “Zoryve allows us to control atopic dermatitis with a new kind of medicine that doesn’t rely upon topical corticosteroids,” he says. The cream is formulated with a well-designed moisturizer base that helps deliver its anti-inflammatory benefits without causing the irritation commonly associated with other treatments.
How Zoryve Works: Inhibiting Inflammation
Zoryve is a phosphodiesterase 4 (PDE4) inhibitor, which means it targets specific enzymes involved in the body’s inflammatory response. By inhibiting these enzymes, Zoryve prevents inflammation from starting, offering proactive control over flare-ups. This mechanism sets it apart from corticosteroids, which suppress inflammation only after it has occurred.
Because of its targeted action, Zoryve can be safely applied anywhere on the skin, even on sensitive areas such as the face or around the eyes, where steroids might cause thinning or other side effects. Dr. Eichenfeld highlights this advantage: “Topical steroids can be problematic in certain parts of the body, like the sensitive skin around the eyes. Zoryve offers a solution with a very low chance of side effects.” For patients with widespread or severe eczema, the ability to treat all affected areas without concern for adverse reactions is a game-changer.
Clinical Trials: Rapid Relief and Sustained Benefits
Zoryve’s effectiveness was demonstrated in phase 3 clinical trials, known as INTEGUMENT-1 and INTEGUMENT-2. In these studies, participants with atopic dermatitis were randomly assigned to receive either Zoryve or a placebo cream daily for four weeks. The results were striking: Zoryve users reported a significant reduction in symptoms, including itch relief, within 24 hours of application. This rapid improvement is a crucial factor for patients, as itching is often the most distressing symptom of eczema.
At the four-week mark, patients using Zoryve experienced greater symptom relief compared to those using the placebo. Researchers evaluated this improvement using several established scales: the Validated Investigator Global Assessment–Atopic Dermatitis (vIGA-AD), which rates eczema severity from 0 (no symptoms) to 4 (severe symptoms); the Worst Itch-Numeric Rating Scale (WI-NRS), which measures itch intensity on a scale of 0 to 10; and the Eczema Area and Severity Index (EASI), which assesses both the extent of the skin affected and the severity of the condition.
Long-term benefits of Zoryve were also confirmed in the 56-week INTEGUMENT-OLE open-label study. Participants who continued using Zoryve showed sustained improvements in both itch and overall skin health throughout the year-long trial, reinforcing the cream’s effectiveness as a long-term treatment option.
Minimal Side Effects: A Safer Alternative
One of the standout features of Zoryve is its safety profile. In the phase 3 trials, less than 3 percent of participants experienced side effects, and those that did reported only mild symptoms such as headache, nausea, or mild irritation at the application site. “Any patient could have a potential reaction to a newly prescribed medication,” Dr. Kleinfelder notes, “but the data on these nonsteroidal agents is very promising for long-term safety.”
This makes Zoryve an attractive option for patients who are concerned about the long-term risks associated with steroids or calcineurin inhibitors. With fewer side effects and no restrictions on duration of use, Zoryve offers both dermatologists and patients a much-needed alternative for managing chronic atopic dermatitis.
Availability and Cost: Making Zoryve Accessible
For those interested in trying Zoryve, the good news is that it is expected to be available for purchase by the end of July 2024, according to Arcutis Biotherapeutics, the company behind the cream. However, as with many new treatments, cost may be a concern. “These new, branded topicals tend to be very expensive,” Dr. Kleinfelder explains. While many insurance plans will cover part of the cost, some patients may still face high out-of-pocket expenses.
To help alleviate these financial barriers, Arcutis Biotherapeutics has launched the Zoryve Direct Program, which offers savings cards to reduce out-of-pocket costs for patients with commercial insurance. Additionally, the Arcutis Cares patient assistance program is available to provide Zoryve at no cost to eligible patients who are uninsured or underinsured.
A Promising New Treatment for Eczema
The FDA’s approval of Zoryve cream marks an important step forward in the treatment of atopic dermatitis. With its ability to provide rapid relief, minimal side effects, and long-term safety, Zoryve offers hope to the millions of individuals struggling to manage this chronic condition. For dermatologists like Dr. Kleinfelder and Dr. Eichenfeld, Zoryve is a welcome addition to the treatment landscape, offering a much-needed option for both adults and children. As more patients gain access to this new therapy, the future of eczema treatment looks brighter than ever.
Recommended For You
